**Table 1.** **Characteristics of the participants at baseline according to HHV8 K8.1 antibody status in NHANES III, the US**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Seropositive (N=308)** | **Seronegative (N=13,685)** | ***P* value** |
| Age | 51.5±17.0 | 43.4±17.1 | < 0.001 |
| 18-40 years | 83 (27.0%) | 6177 (45.2%) |  |
| 40-60 years | 75 (24.4%) | 3568 (26.1%) |  |
| 60-80 years | 105 (34.2%) | 2988 (21.8%) |  |
| ≥80 years | 44 (14.3%) | 946 (6.9%) |  |
| Sex |  |  | 0.859 |
| Male | 141 (45.8%) | 6195 (45.3%) |  |
| Female | 167 (54.2%) | 7490 (54.7%) |  |
| Ethnicity, N (%) |  |  | 0.048 |
| Non-Hispanic white | 110 (35.7%) | 5719 (41.8%) |  |
| Non-Hispanic black | 86 (27.9%) | 3817 (27.9%) |  |
| Mexican-American | 100 (32.5%) | 3540 (25.9%) |  |
| Other | 12 (3.9%) | 609 (4.5%) |  |
| BMI | 26.8±3.3 | 26.4±3.7 | 0.688 |
| Underweight | 10 (3.3%) | 305 (2.2%) |  |
| Healthy weight | 117 (38.4%) | 5248 (38.4%) |  |
| Overweight | 104 (34.1%) | 4685 (34.3%) |  |
| Obese | 74 (24.3%) | 3421 (25.0%) |  |
| Serum triglycerides(mmol/L) | 1.9±1.6 | 1.6±1.9 | 0.018 |
| Healthy | 195 (63.3%) | 9392 (69.1%) |  |
| Borderline high | 42 (13.6%) | 1886 (13.9%) |  |
| High | 71 (23.1%) | 2306 (17.0%) |  |

**Table 2. Mortality rate in relation to HHV8 K8.1 antibody status in NHANES III, the US**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HHV8 K8.1** | **No. of participants** | **No. of deaths** | **Mortality rate**  **(per 100,000 person-years)** | **Mortality rate ratio**  **(95% CI)** | ***P* value** |
| Positive | 308 | 178 | 30.12 | 1.76  (1.52, 2.05) | <0.001 |
| Negative | 13,685 | 5,332 | 17.29 |  |

**Table 3. Multivariable adjusted hazard ratio (HR) and 95% confidence interval (CI) of all-cause death in relation to serum** **HHV8 K8.1 antibody status in NHANES III, the US**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HHV8 K8.1** |  | **HR**  **(95%CI) a** | **HR**  **(95%CI) b** | **HR**  **(95%CI) c** | **HR**  **(95%CI) d** |
| All | Positive | 1.32  (1.03-1.69) | 1.31  (1.03-1.67) | 1.32  (1.03-1.69) | 1.31  (1.02-1.68) |
|  | p value | 0.027 | 0.031 | 0.029 | 0.033 |
| Sex |  |  |  |  |  |
| Men | Positive | 1.26  (0.85-1.86) | 1.24  (0.80-1.84) | 1.26  (0.79-1.89) | 1.27  (0.8-1.86) |
|  | p value | 0.257 | 0.282 | 0.257 | 0.236 |
| Women | Positive | 1.35  (1.04-1.75) | 1.35  (1.04-1.76) | 1.34  (1.03-1.74) | 1.32  (1.01-1.72) |
|  | p value | 0.026 | 0.026 | 0.029 | 0.040 |

a Adjusted for attained age.

b Adjusted for attained age, sex, and ethnicity.

c Adjusted for attained age, sex, ethnicity and body mass index.

d Adjusted for attained age, sex, ethnicity, body mass index and serum TG.

Abbreviations: CMV, cytomegalovirus; CI, confidence interval; HR, hazard ratio.

**Table 4. CVD mortality rate in relation to HHV8 K8.1 antibody status in NHANES III, the US**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HHV8 K8.1** | **No. of participants** | **No. of deaths** | **Mortality rate**  **(per 100,000 person-years)** | **Mortality rate ratio**  **(95% CI)** | ***P* value** |
| Positive | 308 | 60 | 10.15 | 1.96  (1.51, 2.53) | <0.001 |
| Negative | 13,685 | 1,593 | 5.17 |  |

**Table 5.** **Multivariable adjusted hazard ratio (HR) and 95% confidence interval (CI) of CVD death in relation to serum** **HHV8 K8.1 antibody status in NHANES III, the US**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **HHV8 K8.1** |  | **HR**  **(95%CI) a** | **HR**  **(95%CI) b** | **HR**  **(95%CI) c** | **HR**  **(95%CI) d** |
| All | Positive | 1.57  (0.99-2.48) | 1.56  (0.99-2.46) | 1.58  (1.00-2.50) | 1.56  (0.99-2.47) |
|  | p value | 0.054 | 0.053 | 0.048 | 0.056 |
| Sex |  |  |  |  |  |
| Men | Positive | 1.82  (0.95-3.49) | 1.80  (0.94-3.45) | 1.87  (0.99-3.54) | 1.90  (1.02-3.53) |
|  | p value | 0.071 | 0.078 | 0.054 | 0.043 |
| Women | Positive | 1.32  (0.75-2.34) | 1.32  (0.76-2.34) | 1.29  (0.73-2.28) | 1.25  (0.72-2.19) |
|  | p value | 0.341 | 0.343 | 0.387 | 0.430 |

a Adjusted for attained age.

b Adjusted for attained age, sex, and ethnicity.

c Adjusted for attained age, sex, ethnicity and body mass index.

d Adjusted for attained age, sex, ethnicity, body mass index and serum TG.

Abbreviations: CMV, cytomegalovirus; CI, confidence interval; HR, hazard ratio.